Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study

[1]  P. Ravasco,et al.  ESPEN practical guideline: Clinical Nutrition in cancer. , 2021, Clinical nutrition.

[2]  C. Pichard,et al.  Indirect calorimetry: The 6 main issues. , 2020, Clinical nutrition.

[3]  L. Fournel,et al.  Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients. , 2020, Clinical nutrition.

[4]  M. Curran,et al.  Tumor hypermetabolism confers resistance to immunotherapy. , 2020, Seminars in cancer biology.

[5]  Young Hak Kim,et al.  Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy. , 2019, JCI insight.

[6]  T. Creasy,et al.  The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort , 2019, Journal of Translational Medicine.

[7]  J. Uchida,et al.  Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab , 2019, BMC Cancer.

[8]  A. Drilon,et al.  Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. , 2019, The Lancet. Oncology.

[9]  K. Syrigos,et al.  Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. , 2019, The New England journal of medicine.

[10]  M. Sawyer,et al.  Total energy expenditure in patients with colorectal cancer: associations with body composition, physical activity, and energy recommendations. , 2019, The American journal of clinical nutrition.

[11]  L. Zitvogel,et al.  Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  F. Goldwasser,et al.  Resting energy metabolism and anticancer treatments , 2018, Current opinion in clinical nutrition and metabolic care.

[13]  I. Marschner,et al.  Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis , 2018, JAMA oncology.

[14]  Laurence Zitvogel,et al.  Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.

[15]  F. Goldwasser,et al.  Relation between hypermetabolism, cachexia, and survival in cancer patients: a prospective study in 390 cancer patients before initiation of anticancer therapy. , 2017, The American journal of clinical nutrition.

[16]  Nancie J. MacIver,et al.  Nutritional effects on T‐cell immunometabolism , 2017, European journal of immunology.

[17]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[18]  L. Turka,et al.  Immunometabolism of regulatory T cells , 2016, Nature Immunology.

[19]  A. Vigano,et al.  Metabolic, nutritional and inflammatory characteristics in elderly women with advanced cancer. , 2013, Journal of geriatric oncology.

[20]  P. Ravasco,et al.  Individualized nutrition intervention is of major benefit to colorectal cancer patients: long-term follow-up of a randomized controlled trial of nutritional therapy. , 2012, The American journal of clinical nutrition.

[21]  Paula Ravasco,et al.  Definition and classification of cancer cachexia: an international consensus. , 2011, The Lancet. Oncology.

[22]  S. Paterson-Brown,et al.  The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer , 2009, British Journal of Cancer.

[23]  P. Ravasco,et al.  Colorectal Cancer: Intrinsic Characteristics Modulate Cancer Energy Expenditure and the Risk of Cachexia , 2007, Cancer investigation.

[24]  Craig B. Thompson,et al.  Fuel feeds function: energy metabolism and the T-cell response , 2005, Nature Reviews Immunology.

[25]  C. McArdle,et al.  Longitudinal study of resting energy expenditure, body cell mass and the inflammatory response in male patients with non-small cell lung cancer. , 2001, Lung cancer.

[26]  E. Wouters,et al.  Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Roza,et al.  The Harris Benedict equation reevaluated: resting energy requirements and the body cell mass. , 1984, The American journal of clinical nutrition.

[28]  J. B. Weir.  New methods for calculating metabolic rate with special reference to protein metabolism , 1949, The Journal of physiology.